A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.
EGFR Positive Solid Tumors
DRUG: IMGN289
Number of participants with dose limiting toxicities, Up to 2 years
Number of participants with adverse events, Up to 2 years|Area under the plasma concentration versus time curve, Determine the amount of IMGN289 in participants blood (pharmacokinetics), Up to 2 years|Peak plasma concentration (Cmax) of IMGN289, Determine the amount of IMGN289 in participants blood (pharmacokinetics), Up to 2 years|Presence of Human Anti Human Antibody and Human Anti Drug Antibody, Assess whether participants develop an immune response to IMGN289, Up to 2 years|Tumor measurements per RECIST 1:1, Assess preliminary anti-tumor activity, Up to 2 years
This is a Phase 1, first-in-human study to determine the recommended dose of IMGN289 in adult patients with advanced EGFR-positive tumors.